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PEG Polyethylene glycol 
Pfu DNA polymerase Pyrococcus furiousus DNA polymerase 
PE Phycoerythrin  
PMSF Phenylmethylsulfonyl fluoride 
PerCP Peridinin chlorophyll protein 
RNase Ribonuclease 
r-STVII Recombinant  S. typhi Ty21a 
SDS Sodium dodecyl sulphate 
STVII-c  S. typhi Ty21a carries pJWVacII 
Taq DNA polymerase Thermus aquaticus DNA polymerase 
TB Tuberculosis 
TBE Tris-Boric-EDTA 
TE Tris-EDTA 
TSA Tryptic soy agar 
TSB Transformation storage -buffer 
TBS Tris buffered saline 
Ty21a S. typhi Ty21a 
TypJ S. typhi Ty21a transformed with pJW4303 
TypK S. typhi Ty21a transformed with pKK223-3  
U Unit 
UV Ultraviolet 
WHO World Health Organization 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactosylpyranoside 
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Abstract 
 
Despite the discovery of the causative agent of tuberculosis (TB), Mycobacterium 
tuberculosis, more than 120 years ago TB remains a major worldwide health problem. 
Currently, the attenuated strain of M. bovis, Bacille Calmette-Güerin (BCG) is the only 
vaccine available against TB. Although BCG is the world's most widely used vaccine, 
its protective value as an anti-TB vaccine for adults in certain areas of the world, has 
been shown to be low or even non-existent. Thus there is general agreement that new 
novel vaccines are required for TB control and prevention especially in developing 
countries.  
 
In this study, the use of the live attenuated typhoid vaccine, S. typhi Ty21a, for 
development as candidate vaccines against TB was explored in which the organism was 
utilized in a surface display system as well as a carrier of a DNA vaccine. 
 
In the surface display approach, a surface display expression system was developed by 
the construction of a synthetic gene coding for the N-terminal of the ice nucleation 
protein (Inak-n) from Pseudomonas syringae using a method called assembly 
polymerase chain reaction (PCR). In this method, the Inak-n gene was assembled from 
34 overlapping chemically synthesized oligonucleotides in a single step and amplified 
by PCR using specific cloning primers. The gene was cloned into the pCR®2.1-TOPO® 
vector to create a recombinant plasmid designated as pMSInak.  
 
Cloning of a previously constructed 0.82kb synthetic gene known as VacII [which 
contained selected T cell epitopes of several M. tuberculosis genes namely ESAT6, 
MTP40, 38 kDa and MPT64 and further modified to include six consecutive histidine 
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(6xH) residues at the C-terminal end for affinity purification purposes] into pMSInak  
resulted in the fusion of the Inak-n and VacII genes and the resultant recombinant 
plasmid was designated as pMSInak-nVacII. The fused Inak-n::VacII (Inak-nVacII)  
gene from pMSInak-nVacII was then cloned into an expression vector pKK223-3 
resulting in the final construct designated as pKMSInak-nVacII which when 
transformed into S. typhi Ty21a (creating the recombinant strain, r-STVII) and 
expressed allowed the fusion protein, Inak-nVacII, to be displayed on the surface of the 
host bacterial cells. 
 
In the second approach, S. typhi Ty21a was utilized as a carrier of DNA vaccine. In this 
study, S. typhi Ty21a was transformed with a previously constructed DNA vaccine 
called pJWVacII to create a strain called STVII-c. 
 
Both newly constructed vaccine candidates, r-STVII and STVII-c, were shown to be 
safe when tested in C57BL/6 mice. The immunogenicity of the two vaccine candidates 
in C57BL/6 mice were compared with each other and with the appropriate controls.  
 
Each mouse was immunized orally with a dose of 2X109 CFU of r-STVII or STVII-c 
(or controls) on Day 0 and Day 14 respectively and analyses were performed two weeks 
after the second immunization. The spleen cells of vaccinated mice were harvested and 
tested with the following assays: (i) Proliferation of T cells by thymidine uptake (ii) 
IFN-γ in spleen cell culture supernatant by ELISA and (iii) intracellular expression of 
IFN-γ by flow cytometry. In these studies, the purified recombinant protein (Inak-
nVacII) and the synthetic peptides corresponding to single epitopes in the VacII protein 
were used as antigen specific stimulants.  
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The stimulation index of splenocytes from vaccinated mice with r-STVII was found to 
be about 2 fold higher than that of mice vaccinated with STVII-c. Conversely however, 
the concentration of IFN-γ secreted in the culture medium of splenocytes from mice 
vaccinated with STVII-c was 2 fold higher than that of r-STVII.  
 
Intracellular cytokines analysis showed that both CD4+ and CD8+ T cells produced   
IFN-γ when splenocytes were stimulated in vitro with purified Inak-nVacII or the single 
epitope peptides. The data also showed that IFN-γ produced by CD4+ T-cells from mice 
vaccinated with STVII-c was 1.3 fold higher than mice vaccinated with r-STVII when 
the cells were stimulated with purified Inak-nVacII. However, the data also showed that 
CD8+ T-cells from mice vaccinated with STVII-c secreted 1.5 fold higher IFN-γ than 
mice vaccinated with r-STVII when stimulated with the same protein. 
 
The importance of targeting both CD4+ and CD8+ T cells to stimulate effective 
protection against M. tuberculosis have been noted by many workers. In conclusion, the 
results obtained suggest that oral vaccination with the two new vaccine candidates 
produced in this study might be an efficient method for generating a broad and 
protective immune response against TB in the mouse model. The data generated by this 
study therefore may have an important impact in the strategy for developing newer 
vaccines against TB in humans. 
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PEMBANGUNAN Salmonella typhi Ty21a SEBAGAI VAKSIN 
ORAL YANG BERPOTENSI TERHADAP TUBERKULOSIS: KAEDAH  
PAMERAN PERMUKAAN DAN PEMBAWA VAKSIN DNA UNTUK GEN 
SINTETIK MULTIEPITOP MIKOBAKTERIA 
 
 
Abstrak 
 
Walaupun agen penyebab tuberkulosis (TB) iaitu Mycobacterium tuberculosis telah 
ditemui lebih daripada 120 tahun yang lalu, TB masih kekal sebagai antara masaalah 
kesihatan terbesar di dunia. Pada waktu ini strain M. bovis teratenuat, Bacille Calmette-
Güerin (BCG) masih merupakan satu-satunya vaksin yang ada terhadap TB. Walaupun 
BCG merupakan vaksin yang paling tinggi kegunaannya di dunia, keberkesanan 
perlindungannya sebagai vaksin anti-TB untuk orang dewasa adalah rendah ataupun 
tiada lansung seperti yang ditunjukkan dalam kajian di beberapa tempat di dunia. Oleh 
itu adalah dipersetujui umum bahawa vaksin-vaksin baru perlu dibangunkan untuk 
membantu kawalan dan pencegahan TB terutamanya di negara-negara membangun. 
 
Di dalam kajian ini, penggunaan vaksin hidup teratenuat untuk demam tifoid, S. typhi 
Ty21a, sebagai vaksin terhadap TB telah diterokai melalui penggunaannya dalam sistem 
pameran permukaan dan sebagai pembawa vaksin DNA. 
 
Di dalam pendekatan  pameran permukaan, sistem ekspresi permukaan telah disediakan 
melalui pembangunan gen sintetik yang mengkodkan terminal-N "ice nucleation 
protein", (Inak-n), daripada Pseudomonas syringae dengan menggunakan kaedah 
tindakbalas rantaian polimerase [polymerase chain reaction (PCR)] pemasangan. 
Melalui kaedah ini gen Inak-n telah dipasang dalam satu langkah dengan menggunakan 
34 oligonukleotida sintetik bertindih yang kemudiannya di amplifikasikan melalui PCR 
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dengan menggunakan primer spesifik. Gen ini telah diklonkan kedalam vektor 
pCR®2.1-TOPO® untuk menghasilkan plasmid rekombinan pMSInak. 
 
Pengklonan gen sintetik bersaiz 0.82kb bernama VacII (yang mengandungi epitop sel T 
terpilih dari gen-gen M. tuberculosis iaitu ESAT6, MTP40, 38 kDa dan MPT64 serta di 
modifikasikan untuk mengandungi 6 residu histidina di terminal C protein ini bagi 
tujuan penulenan afiniti) yang telah dibangunkan sebelum ini, kedalam pMSInak telah 
menghasilkan gabungan gen Inak-n dan VacII. Plasmid rekombinan yang dihasilkan di 
namai pMSInak-nVacII. Gen bergabung Inak-n::VacII (Inak-nVacII) daripada 
pMSInak-nVacII kemudiannya telah diklonkan ke dalam plasmid ekspresi pKK223-3 
untuk menghasilkan plasmid rekombinan pKMSInak-nVacII. Plasmid ini apabila 
ditransformasikan ke dalam S. typhi Ty21a (dan menghasilkan strain r-STVII) dan 
diekspresikan akan menyebabkan protein bergabung ini, protein Inak-nVacII, 
dipamerkan di permukaan sel perumah ini. 
 
Di dalam pendekatan kedua, S. typhi Ty21a telah digunakan sebagai pembawa vaksin 
DNA. Di dalam kajian ini S. typhi Ty21a telah ditransformasikan dengan vaksin DNA 
yang telah dibangunkan sebelum ini dan dinamai pJWVacII, untuk menghasilkan strain 
STVII-c. 
 
Kedua-dua calon vaksin yang baru dibangunkan ini, r-STVII and STVII-c, didapati 
selamat bila diuji dalam mencit C57BL/6. Imunogenisiti kedua-dua calon vaksin ini 
dibandingkan di antara satu sama lain dan dengan kontrol-kontrol yang sesuai dalam 
mencit C57BL/6. 
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Setiap mencit imunisasikan secara oral dengan dos yang mengandungi 2X109 CFU 
bakteria r-STVII atau  STVII-c (atau kontrol) pada Hari Ke 1 dan Ke 14 dan analisis 
dijalankan 2 minggu selepas imunisasi ke dua. Sel spleen daripada mencit yang 
divaksinasikan telah dituai dan diuji dengan asai berikut: (i) Percambahan sel T melalui 
kaedah ambilnaik timidina (ii) IFN-γ dalam supernatan sel spleen melalui kaedah 
ELISA (iii) Ekspresi intrasel IFN-γ melalui flositometri. Dalam kajian-kajian ini protein 
rekombinan Inak-nVacII yang ditulenkan serta peptida-peptida sintetik yang mewakili 
epitop-epitop tunggal dalam protein VacII telah digunakan sebagai antigen spesifik 
perangsang. 
 
Splenosit daripada mencit yang divaksinasikan dengan r-STVII di dapati mempunyai 
indeks stimulasi  2 kali ganda lebih tinggi daripada mencit yang divaksinasikan dengan 
STVII-c. Sebaliknya, kepekatan IFN-γ yang dirembeskan ke dalam medium kultur 
splenosit dari mencit yang divaksinasikan dengan STVII-c adalah 2 kali ganda lebih 
tinggi berbanding spelnosit daripada mencit yang divaksinasikan dengan r-STVII. 
 
Analisis sitokin intrasel menunjukkan bahawa kedua-dua sel T CD4+ dan CD8+  
menghasilkan IFN-γ apabila splenosit di ransangkan secara in vitro dengan Inak-nVacII 
yang ditulenkan ataupun peptida epitop tunggal. Data juga menunjukkan bahawa sel T 
CD4+ daripada mencit yang divaksinasikan dengan STVII-c menghasilkan 1.3 ganda 
lebih banyak IFN-γ berbanding sel T CD4+ daripada mencit yang divaksinasikan dengan 
r-STVII apabila diransangkan dengan protein Inak-nVacII yang ditulenkan. Walau 
bagaimanapun, sel T CD8+ daripada mencit yang divaksinasikan dengan STVII-c 
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menghasilkan 1.5 ganda lebih banyak IFN-γ berbanding sel T CD8+  daripada mencit 
yang divaksinasikan dengan r-STVII apabila diransangkan dengan protein yang sama. 
 
Kepentingan mensasarkan kedua-dua sel T CD4+ and CD8+ untuk meransang 
perlindungan yang berkesan terhadap M. tuberculosis telah di nyatakan oleh ramai 
penyelidik. Sebagai rumusan, keputusan yang didapati mencadangkan bahawa vaksinasi 
oral dengan kedua-dua calon vaksin yang dihasilkan dalam kajian ini kemungkinan 
merupakan kaedah berkesan untuk menjana tindakbalas imun yang luas dan memberi 
perlindungan terhadap TB dalam model mencit. Oleh itu data yang dijanakan oleh 
kajian ini mempuyai impak yang besar  terhadap strategi bagi membangunkan vaksin-
vaksin baru terhadap TB dalam manusia.  
 
 
 Introduction 
 
1 
Chapter One 
Introduction 
1.1. Background 
Tuberculosis (TB) is an infectious disease caused by the tubercle bacillus, 
Mycobacterium tuberculosis which can attack different organs in the body, but most 
commonly the lungs. M. tuberculosis is a very serious human pathogen, and the World 
Health Organization have declared it among the leading fatal infectious diseases, as it 
remains the second leading killer infection after HIV/AIDS (Table 1.1). More than 3 
million people die from TB (including 0.9 million HIV patients), and nearly 8 million 
new cases of this disease are reported each year (WHO, 2000, Sacksteder and Nacy, 
2002). The vast majority of the reported TB cases and deaths occur in developing 
countries, due to poverty, rapid population growth, malnutrition, homelessness, 
crowded shelter, and lack of medical care. Since TB is easily transmissible between 
persons, the increase in TB in any sector of the population represents a risk to all 
sectors of the population (Dye et al., 1999, Dye, 2000, Ainsa et al., 2001). The global 
incidence rate of TB is growing at an annual rate of approximately 0.4% (WHO, 2003). 
  
1.2. Human TB: A historical perspective 
Medical historians suggest that TB is among the oldest infectious diseases that have 
affected humankind more than 5000 years ago. Tissue samples from Egyptian 
mummies grave sites, dated back to 3400 B.C., have shown evidence, either by 
morphological sign of TB, and/or by DNA analysis, that is consistent with an original 
M. tuberculosis complex similar to one that can be found today (Morse et al., 1964, 
Crubezy et al., 1998, Zink et al., 2003). Around 460 B.C., Hippocrates described the  
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               Table1. 1. Deaths from diseases for which vaccines are needed 
Diseases Deaths  % 
AIDS 2,285,000 44.29 
Tuberculosis 1,498,000 29.03 
Malaria 1,110,000 21.15 
Schistosomiasis    150,000 2.90 
Leishmaniasis      42,000 0.81 
Trympanosomiasis      40,000 0.77 
Chagas disease      17,000 0.32 
Dengue     15,000 0.29 
Leprosy       2,000 0.03 
Total deaths 5,159,000 100.00 
                 Modified from: M. Kremer, Public Policies to Stimulate the Development of  
                 Vaccines and Drugs for the Neglected Diseases. CMH Working Paper Series  
                 Paper No. WG 2:8. 
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clinical features of both pulmonary and spinal TB: he wrote that TB was the most 
common disease of humans and can be transmitted from man to man, and he further 
noted that it was nearly always fatal. 
 
TB has been known by many names such as Pthisis (Wasting), Pott’s disease (TB of the 
bones), Lupus vulgaris (TB of the skin), Consumption (the “classic” case of lung 
disease), and White Plague. Tuberculosis-like diseases were reported in ancient 
writings of the Hindus and Chinese (Ayvazian, 1993, Daniel et al., 1994). However, the 
first description of the transmissible nature of TB from a consumptive to healthy person 
was clearly established by the English physician Benjamin Martin in 1722.  The control 
of TB  was started in 1868, when a French military physician, Jean-Antoine Villemin 
proved that TB was contagious (Barnes, 2000). In Berlin on the 24th of March, 1882, 
Robert Koch announced the discovery of the TB bacillus after his success in growing 
them in culture. At that time, TB was very common and killed one out of every seven 
people living in the United States and Europe. Thus, this discovery was the most 
important step taken towards the control and elimination of this deadly disease (Barnes, 
2000, Kaufmann, 2003). Nevertheless, in the 1900’s, TB remained a common disease 
among the elderly people, and the only way suggested to lift the burden of the disease 
from the old people was to protect the future generations: infants, children, and the 
youth, before becoming infected. Thus, soon after the discovery of the tubercle bacilli 
by Robert Koch, the Sanatorium era began (Bloom and Murray, 1992). 
 
Following these dates, TB declined in industrialized countries, as a result of the 
introduction of the effective vaccine Bacille Calmette-Güerin (BCG) in 1906, and the 
anti-tuberculosis drugs, streptomycin in 1944 and isoniazid in 1952, which cured 
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established disease, and prevented progression of TB infection to disease (Raviglione  
et al., 1995, Maes, 1999). Consequently, there was a general decline in the attention to 
research in TB. However, hopes that the disease could be completely eliminated have 
declined since the rise of drug-resistant strains in the mid 1980s but this phenomenon 
have initiated renewed interest in the disease (Cole, 1994).  
 
1.3. Epidemiology of TB in humans 
In April 1993, the WHO took the exceptional step of declaring TB to be a global health 
emergency gaining attention to the problem that had been largely ignored over the 
preceding few decades (WHO, 1994). Since World War II until 1984, the incidence of 
the disease declined in Western Europe and North America due to anti-tuberculosis 
medications, awareness of the disease, and improved living conditions. TB has declined 
in USA from 84,304 reported cases in 1953 to 22,255 cases in 1984 (Fig.1.1), but the 
progressive decline in incidence stopped and the case level plateaued and then 
increased by 5% to 23,495 in 1989, and by 6% in 1990 (Groves, 1997).  
 
Today, it is estimated that 2 billion people i.e., one third of the world's population are 
infected with M. tuberculosis. Over 30 million of those infected people harbour active 
disease. Every minute, more than 10 individuals develop TB amounting to 8 million 
new cases annually,  and over 2 million of those TB sufferers are expected to die of the 
disease, making this disease the leading cause of death from a single pathogen in the 
world (Dye et al., 1999). The incidence of TB has increased dramatically in areas with 
high rates of HIV infection.  
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Fig.1. 1. Cases of TB reported to the Center for Disease Control and Prevention (CDC), 
in United States from 1953-1992. Ë Changes in case definition, data obtained from 
Groves(1997)  
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Thus, TB is the leading infectious cause of death among people more than 5 years of 
age in South-East Asia, and accounts for approximately 40% of all the cases of TB in 
the world. Within South-East Asia, more than 95% of cases are found in India, 
Indonesia, Bangladesh, Thailand, and Myanmar (Murray et al., 1990, Kochi, 1991, 
Bloom and Murray, 1992). The Ministry of Health in Malaysia reported that 10,000- 
12,000 new cases were registered every year from 1972-1995. In the year 2000, WHO 
reported that 8,156 smear positive cases were notified in Malaysia (WHO, 2003).  
 
Numerous factors have been associated with the reappearance and increased TB 
incidence which include: immigration from TB endemic areas, the emergence of multi-
drug resistant (MDR) strains, and increased numbers of immunocompromised patients, 
especially HIV-infected. The above statistics put TB in the unfavorable list of the top 
major killers, together with AIDS and malaria  (Kabra et al., 2002). 
 
1.4. The TB organism: Mycobacterium tuberculosis 
Mycobacteria belong to the family Mycobacteriaceae and the order Actinomycetales. 
They are non-motile, non-spore forming, straight or slightly curved rod shaped 
microbes, 1-4 μm in length, and between 0.3-0.6 μm in diameter, making them smaller 
than most bacterial pathogens (Iseman, 2000). Mycobacteria are considered ''acid-fast'', 
which means that they retain dyes following an acid-alcohol decolorization step, and 
this characteristic is related to the complex cell wall structure that contains derivatives 
of mycolic acid (Floyd et al., 1992). These organisms usually contain granules and 
vacuoles but they do not form capsules, flagella, or spores.  In culture, these organisms 
grow slowly and divide once every 18 to 24 hours. They can be grown for 2 to 12 
weeks, until they reach 103-104 in number  (Dannenberg, 1992). They are resistant to 
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drying especially in sputum, where they can remain viable for 6-8 months. They are 
also resistant to 3% HCl and 6% H2SO4, and to 4% NaOH. However, Mycobacteria are 
sensitive to moist heat at 60ºC for 30 min, to disinfectants such as alcohol, 
glutaraldehyde, formaldehyde, and Ultraviolet (uv) irradiation (Tortora et al., 2001). 
 
Several species of mycobacteria with similar growth characteristics and biochemical 
reactions are classified together into the M. tuberculosis complex (Cole, 2002). In 
addition to M. tuberculosis, the complex  includes M. bovis, M. africanum, and M. 
microti which are also causative agents of TB in mammals (Brosch et al., 2000). M. 
bovis is the causal agent of bovines and infects a wide variety of mammalian species 
including humans. M. africanum has been reported to infect humans in sub-Saharan 
Africa as well as monkeys (Thorel, 1980). M. microti causes TB in small rodents such 
as voles (Hart and Sutherland, 1977). 
 
Although the mycobacterial cell wall is weakly Gram-positive, this cell wall 
characteristic do not really indicate whether M. tuberculosis is more related to Gram- 
positive or Gram-negative bacteria since it has features of both in this respect. Recently 
Fu & Fu-Liu (2002) showed that M. tuberculosis is more related to gram-negative 
bacteria by construction of a genome tree based on the conserved gene content which 
revealed the evolutionary distance between nearest ancestral units.  
 
1.5. Chemical composition of the M. tuberculosis cell wall structure  
The cell walls of Gram-positive bacteria are made up of peptidoglycan layers combined 
with teichoic acid molecules, whereas those of Gram-negative bacteria contain much   
less peptidoglycan, with no teichoic acid (Fig.1.2). The Gram-negative cell wall has a 
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true lipid bilayer outer membrane that is attached to the characteristic endotoxic 
lipopolysaccharide (Sussman, 2002).  
 
However, the cell wall structure of M. tuberculosis deserves special attention because it 
is unique among prokaryotes and may be a major determinant of the virulence of the 
bacterium. Biochemical and electron microscopic studies indicate that the cell wall of 
M. tuberculosis possesses four layers. The first layer (innermost) is the peptidoglycan 
layer while the next three surface layers are composed of lipids such as mycolic acid, 
glycolipids, cord factor and wax D (Sussman, 2002). The most important  feature of the 
mycobacterial cell wall is the presence of up to 60% of the total mass of lipid 
components, particularly, the very long-chain mycolic acids, which are attached by 
ester bonds to the terminal arabinose units of the arabinogalactan, thereby forming a 
pseudolipid bilayer (Fig.1.2) (Brennan and Besra, 1997, Brennan, 2003).  
 
In the cell wall of M. tuberculosis the lipids fall under two important classes, 
sulpholipids and trehalose dimycolates, which are also known as, cord factors. The 
sulpholipids are strongly acidic compounds covalently bound to trehalose sulphate. 
They may be involved in the virulence of M. tuberculosis as they have been shown to 
prevent phagosome/ lysosome fusion in macrophages infected with M. tuberculosis. 
Several waxes are also present, which increase the impermeability of the mycobacterial 
cell wall (Slots and Taubman, 1992).  
 
This highly hydrophobic cell wall is not only responsible for the acid-fastness, but also 
for resistance to acidic or alkaline chemicals, and for its relative stability in simple 
disinfectants, in addition to the high adjuvanticity of the cell wall (Tortora et al., 2001).  
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Fig.1. 2. Comparison between Gram-positive, Gram-negative and Mycobacterial cell wall. 
               Adapted from: http://web.uct.ac.za/depts/mmi/lsteyn/cellwall.html.
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1.6. Genetics of M. tuberculosis 
Genome sequencing of M. tuberculosis was completed in 1998 and analysis of the data 
show an estimate of 4,411,529 base pairs and 3,924 predicted open reading frames. M. 
tuberculosis is a difficult organism to study because of some unique features. One of 
these features is the high content of guanine and cytosine in its DNA. The high GC 
content of 65.6% may be one survival strategy employed by bacteria, since stability of 
DNA increases directly with number of GC bonds (Cole et al., 1998).  
 
1.7. Pathophysiology of TB  
1.7.1. TB, the disease 
Tuberculosis (TB) is defined as a pulmonary and systemic infectious disease caused by 
M. tuberculosis and characterized by formation of granulomas and by cell-mediated 
hypersensitivity, in which M. tuberculosis multiply and attack different parts of the 
body (Daniel et al., 1994). The course of the disease is the result of a balance between 
the severity of the causative agent and the immunity of the host. Infection is 
encountered by inhalation of a droplet nuclei (1-5 μm in diameter) carrying the 
organism. Inside the body, the tubercle bacilli do not produce endotoxins or exotoxins 
(Edwards and Kirkpatrick, 1986, Dannenberg, 1992, Gonzalez-Juarrero et al., 2001). 
Damage is caused by uncontrolled progressive, chronic inflammation and by the 
organisms living inside macrophages. TB is generally classified into latent infection and 
active infection. 
 
In latent TB infection, M. tuberculosis is present in the body but there are no signs or 
symptoms of TB. People who have latent infection cannot spread the bacteria to other 
people but are at risk of developing active TB disease. Patients with active TB disease 
 Introduction 
 
11
exhibit signs and symptoms of disease. It occurs in 10% of those who are infected with 
M. tuberculosis. People who have active TB disease can spread the bacteria to others. 
TB can be categorized into two main types, according to where in the body the infection 
manifests itself. The two types are described as pulmonary and extrapulmonary (or non-
pulmonary) TB. Pulmonary TB accounts for most of the cases of infection and about 
85% of TB deaths (Rossman and MacGregor, 1995).  
 
Extrapulmonary TB is a general term that encompasses TB infection that has 
disseminated to various sites around the body from the lungs. Extrapulmonary TB can 
affect many different parts of the body including lymphatic, pleural, spinal, bones and 
joints, meninges, genitourinary, peritoneal, and miliary (disseminated) TB. Pleural and 
lymphatic TB are the most common types of extrapulmonary TB (Fig 1.3). 
Extrapulmonary TB is very common among patients co-infected with HIV and 
pulmonary TB; 60-80% of these patients develop extrapulmonary TB in contrast to 17% 
of non-HIV patients who develop extrapulmonary TB. In addition, 30% of children with 
primary pulmonary TB infection develop extrapulmonary TB (Rossman and 
MacGregor, 1995). 
 
1.7.2. Symptoms of TB 
Most people infected with TB have inactive disease, which causes no symptoms. 
However, in primary pulmonary TB more than half of the people with this type of TB 
have no symptoms other than fever. In secondary or reactivation TB various symptoms 
are involved including cough, chest pain, night sweats, poor appetite and loss of weight. 
As the illness progresses, people may cough up blood (hemoptysis) and develop severe 
breathing problems (Mandell et al., 1990). 
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Fig.1. 3. Percentage of extrapulmonary TB by anatomic sites. 
(Rossman and MacGregor, 1995). 
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The symptoms of extrapulmonary TBs depend on where the TB has spread. Thus, if TB 
affects the lymph nodes, it can cause swollen glands, usually at the sides and base of the 
neck. In TB of the bones and joints, there can be a hunchback curvature of the spine or 
pain and swelling of a knee or hip, with patients usually developing a limp. 
Genitourinary TB, can cause pain in the side (between the ribs and hip), frequent and 
painful urination, with  blood in the urine (Rossman and MacGregor, 1995). 
 
1.7.3. Transmission of M. tuberculosis 
Transmission of M. tuberculosis (infection) occurs when people with active pulmonary 
disease expel millions of water droplets containing M. tuberculosis into the air. These 
droplets are small airborne particles of water that can remain floating in the air for 
several hours (Baum and Wolinsky, 1983). Every one may acquire M. tuberculosis 
through these airborne particles regardless of age, sex and race, but not everyone 
exposed to the bacterium becomes infected nor does everybody develops clinical 
symptoms of TB. Studies conducted worldwide have shown a rapid spread of TB in 
crowded living conditions, such as in nursing homes, hospitals (Clarke and Higgins, 
1995), homeless shelters, schools, military barracks, and prisons (Nettleman, 1993, 
MacIntyre et al., 1999, Brewer et al., 2001, Drobnieuski et al., 2003). Passengers on 
commercial aircrafts are particularly susceptible for the transmission of TB among 
humans (Bignell, 1994, Miller et al., 1996, Al-Jahdali et al., 2003). 
 
There are at least three factors influencing transmission of M. tuberculosis: (1) the 
number of viable bacilli in patient’s sputum and their concentration in the air, (2) the 
length of time an exposed person breathes the contaminated air, and (3) the immune 
status of the exposed individual (Horsburgh, 1996). 
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1.8. Immune response to TB 
1.8.1. Early response  
Early after the initial infection with M. tuberculosis, granulocytes respond to this 
invasion and migrate from the blood into tissues and participate in an early 
inflammatory response. However, there is some controversy on the involvement of 
these cells in the killing of  M. tuberculosis (Denis, 1991). M. tuberculosis induced an 
influx of leukocytes including polymorphonuclear neutrophils (PMNs), lymphocytes, 
and monocytes (Appelberg and Silva, 1989, Appelberg, 1992). The importance of 
neutrophils in host defenses against mycobacteria has been dismissed because the 
neutrophil has a short life span, and the bacilli grow inside macrophages, and are thus 
protected from the phagocytotic activity of neutrophils. These two reasons were 
supported by the findings of Denis (1991) who reported that human neutrophils were 
unable to kill M. tuberculosis. Furthermore, Pedrosa et al., (2000) showed in their study 
that M. tuberculosis is associated with or within macrophages and not with neutrophils. 
It has also been shown that eosinophils may be play a role in the inflammatory response 
initiated by M. tuberculosis (Castro et al., 1991). These findings have led the 
researchers to focus their efforts on the M. tuberculosis inactivating mechanisms of 
macrophages instead of granulocytes.  
  
1.8.2. Pathogenicity and initial defense against M. tuberculosis infection   
1.8.2.1. Primary TB 
Primary TB is a disease, or a response to infection by a host who have not been 
previously exposed to/or vaccinated against TB. After entry into the host, the droplet 
nuclei are carried down the bronchial tree and become implanted in the alveoli. The 
bacteria are ingested by the resident alveolar macrophages (AM) which kill or limit the 
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replication of mycobacteria, due to the action of lysosomal enzymes and reactive 
nitrogen and oxygen species (Fang, 1997, Miller and Britigan, 1997, van Crevel et al., 
2002). However, mycobacteria resist lysosomal degradation and escape from the 
phagolysosomes into the cytoplasm of the macrophage, where somehow, they manage 
to survive and even multiply until their number reaches 103-104 which is sufficient to 
elicit a cellular immune response (Smith and Wiengeshaus, 1989). Finally, 
mycobacteria burst out of the infected macrophage, killing it and then infect other 
macrophages in the area. As macrophages die by necrosis, they pour their lysosomal 
contents into the surrounding area or in the neighboring lung tissue, causing tissue 
damage, and initiating an inflammatory response. These events may be the most 
important stages in establishing infection in the host (Sompayrac, 1999).  
  
Inflammation is necessary for the proper functioning of the host defenses, including the 
immune defenses, because it attracts circulating antimicrobial factors to the site of 
infection. These include phagocytes, lymphocytes, antibodies, complement and other 
antimicrobial components of plasma. The immune system continues to send 
macrophages to destroy the bacteria resulting in an accumulation of living and dead 
macrophages at the site of infection creating a structure called a tubercle (Dannenberg, 
1989, van Crevel et al., 2002). Two to three weeks after infection, cellular immunity 
developed, with antigen-specific T lymphocytes that proliferate within the early 
tubercles, and activated macrophages to kill the intracellular mycobacteria. As a result, 
most of the organisms die, and lesions in the lung and draining lymph nodes heal by 
fibrosis, and sometimes calcify to inhibit extracellular growth of the remaining 
mycobacteria. Some of these microorganisms remain viable for long periods (Daniel, 
1994). 
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1.8.2.2. Secondary TB  
 The standard assumption of the recurrence of TB is by reactivation of the existing 
latent infection. However, reinfection by a new strain is also possible. Reactivation can 
occur when the immune system is weakened, as a result of malnutrition, and co-
infection by other diseases such as AIDS (Chan et al., 1996). When alveolar 
macrophages fail to kill the mycobacteria, the immune system’s next line of defense is 
to form granulomas around the infected macrophages. Granulomas are, essentially, 
layers of T-cells sealing the mycobacteria inside a barrier from which it cannot escape. 
Two to three weeks after the inhalation of the M. tuberculosis, the host possesses both 
cell mediated immunity (CMI) and delayed-type hypersensitivity (DTH). With the 
emergence of DTH, infected macrophages in the interior of each granuloma are killed as 
the periphery becomes fibrotic and slowly become caseated (cheesy-like, semi-solid 
debris composed of lipid and proteins from tubercle bacilli and macrophages), and 
eventually merge into larger lesions (Dannenberg 1991). With time, proteases produced 
by activated macrophages liquefy the caseous material and form air filled tuberculous 
cavities that provide the bacilli with a suitable extracellular site for reproduction. 
Rupture of a tuberculous cavity into the pleural space may lead to the bacteria extending 
into the blood stream via regional nodes, where they are ingested by monocytes in the 
blood. Moreover, as the expanding lesion erodes through the wall of the bronchus, the 
liquefied content is discharged and thus allowing the bacteria to spread to and colonize 
virtually every organ in the host. A well aerated cavity is also formed where the 
organisms can actively proliferate (Dannenberg, 1991). Since inflammation of the 
surface of the bronchi causes increased mucus secretion and stimulation of the cough 
reflex, patients cough up sputum. Mycobacterial growth is not kept under control and 
can cause major destruction of tissues. In advanced TB, blood vessels may become 
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exposed to the cavities produced by necrosis, and patients may die of hemorrhage, if 
these vessels are ruptured (van Crevel et al., 2002). Secondary TB usually becomes 
noticeable one or two years after the primary disease, probably because it takes that 
long a time to develop full blown delayed-type hypersensitivity. 
 
1.8.3. Immunity to TB 
1.8.3.1. Humoral immunity against TB 
Humoral immunity is mediated by antibodies produced by B cells and their progeny 
when a foreign antigen enters the blood stream of a mammal. These antibodies bind 
specifically to antigens eliciting the immune response. The immune system then 
neutralizes or eliminates them from the body through ingestion and degradation of the 
antibody-antigen complex by phagocytes. One more method of elimination of foreign 
antigens is by degradation of viruses and other proteinaceous substances by proteolysis 
and killing of bacteria by cell lysis  (Abbas and Lichtman, 2001).  
 
Antibodies are produced in response to mycobacterial infection, but there is no definite 
evidence that immunoglobulins (Ig) play a significant role in  protective immunity to 
TB (Dunlap and Briles, 1993). The role of the polymorphonuclear cells (PMNs) in TB 
is not well understood, but studies have shown that PMNs can diminish growth of M. 
tuberculosis by non-oxidative processes (Brown, 1987). 
 
During the primary infection, IgM antibody responses are directed chiefly at nonspecific 
polysaccharide antigens. They develop early but never reach high titer, and this level 
does not correlate well with the presence or absence of active disease (Daniel and 
Debanne, 1987, Daniel et al., 1994). 
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Levels of IgG antibody detectable by ELISA and other immunoassay are usually an 
indication of active TB. Studies with many TB antigens using several techniques 
showed that few control subjects have measurable IgG antibody levels (Daniel and 
Debanne, 1987).  
 
IgA antibodies have been found at low levels in the serum of patients with active TB, 
but not in control subjects (Daniel and Debanne, 1987). Recently, Cardona, et al., 
(2002) showed for the first time the stimulation of antibodies against the glycolipids 
from the M. tuberculosis cell wall which include diacyltrehaloses (DAT) and 
sulpholipid I (SL-I) in murine models. Their results showed that these antigens elicit 
higher antibody levels than protein antigens like the Ag85 complex, culture filtrate 
proteins (CFP) and purified protein derivative (PPD).  
 
The results from the studies described above suggest that although humoral immune 
system is induced by M. tuberculosis infection, it appears to play little role in protecting 
the host from the disease progression. 
 
1.8.3.2. Cellular immunity against TB 
Cell-mediated immunity (CMI) response is believed to involve different T-cell subsets. 
T-cells can be divided into two major classes, CD4+ and CD8+ T-cells. CD4+ and CD8+ 
T-cell recognition of antigens requires that the antigens are processed and displayed on 
the surface of antigen presenting cells (APC) bound to specialized molecules called 
major histocompatibility (MHC) molecules. MHC molecules include class I and class II 
molecules (Germain, 1999). 
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One feature characterizing the class I MHC molecules is that they typically present 
peptides derived from intracellular antigens such as endogenous proteins or viral 
proteins synthesized during infection, and they are expressed on all nucleated cells. 
Peptide-MHC-I complexes are recognized by CD8+ T-cells. These cells have cytolytic 
activity and will kill the target cells upon peptide-MHC recognition. They also have 
cytolytic functions and are generally called cytotoxic T lymphocytes (CTL). When a 
CTL recognizes its target, it releases cytotoxic molecules, perforins which will induce 
apoptosis in the target cells (Abbas and Lichtman, 2001, Esser et al., 2003). 
 
Class II MHC molecules are expressed by APC only and typically present peptides 
derived from extracellular antigens that have been internalized by the APC. The 
peptide-MHC complexes are mainly recognized by CD4+ T-cells.  CD4+ T-cells can be 
further divided into two subsets of effector CD4+ T lymphocytes, called T helper type 1 
(Th1) and 2  (Th2) respectively, which differ in their cytokine production (Abbas and 
Lichtman, 2001, Esser et al., 2003). Th1 cells are important in infections with 
intracellular bacteria such as M. tuberculosis and they produce interferon gamma    
(IFN-γ), interleukine-12 (IL-12) and tumor necrosis factor (TNF)-α. On the other hand, 
Th2 cells are important in antibody-mediated (humoral) immunity. These cells produce 
cytokines such as IL-4, IL-5, IL-6 and IL-10 that provide the necessary signals to B 
cells in producing antibody (Abbas and Lichtman, 2001, Esser et al., 2003). 
 
Cell-mediated immunity is the major protective immune response against mycobacterial 
infection. T-cells contribute in the acquired immune response by means of two major 
functions. First, they produce cytokines, particularly IFN-γ which is the major activator 
of antimicrobial macrophage functions. This cytokine is produced by all T stimulated 
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cells in response to mycobacterial infection, such as CD4+ and CD8+ T-cell clones 
(Schaible et al., 1999). Second, these cells also express cytolytic activities, whereby 
they lyse infected target cells (Kaufmann, 1999). 
 
CD4+ cells of the Th1 type play a key role in protective immunity against M. 
tuberculosis. This was established, initially, in experimental models of TB (Orme and 
Collins, 1984). In humans, the strongest evidence for a predominant role of CD4+ T-
cells in protective immunity is the increased susceptibility of HIV-infected populations 
to the development of active TB (Caruso et al., 1999, Orme, 2001). Once macrophages 
are activated, and the phagocytosed bacteria are processed in the endosomal 
compartment of the macrophage, peptides will be presented to CD4+ T-cells in 
association with class II major histocompatibility complex (MHC) molecules on the 
surface of the macrophage. CD4+ T-cells recognize the complex and become activated, 
and consequently induce the production of Th1 cytokines, IL-2 and IFN-γ (Flynn et al., 
1993).  
 
The role of CD8+ T-cells starts when mycobacteria gain access to the cytoplasmic 
compartment of macrophages and become associated with MHC-I molecules. This 
antigen-MHC-I complex can then stimulate CD8+ T-cells to produce cytokines such as 
IFN-γ and TNF-α to activate macrophages. CD8+ T-cells facilitate the release of intact 
bacteria entrapped in macrophages. In this way, bacteria can be released from 
ineffective macrophages and phagocytosed by more efficient cells. Strong evidence 
from mouse experiments suggests a major role of CD8+ T-cells, in addition to CD4+      
T-cells, in protection against TB (Flynn et al., 1992, Lewinsohn et al., 2000, Smith and 
Dockrell, 2000, Klein and Fox, 2001). Consequently, it is most likely that the different 
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T-cell populations are required for optimum protection since they have diverse, yet 
versatile mechanism (Triccas et al., 2002).  
 
The protein and non-protein antigens of M. tuberculosis are strong stimuli for induction 
of cytokine production in human mononuclear phagocytes which most likely affect the 
outcome of infection at any stage of the M. tuberculosis infection (van Crevel et al., 
2002). Studies in cytokine production during M. tuberculosis infections have shown that 
several, proinflammatory cytokines, particularly IFN-γ, TNF-α, IL-1, IL-6, IL-12, and 
IL-18 are produced after the recognition of M. tuberculosis by phagocytic cells      
(Table 1.2). These cytokines act in the autocrine or paracrine networks to influence the 
function of cells in immunity to M. tuberculosis (van Crevel et al., 2002).  
 
Tumor necrosis factor alpha (TNF-α) plays an important role in the host response to 
infection with M. tuberculosis. In mice, TNF-α is essential for formation of tuberculous 
granulomas which serves to isolate the virulent bacterium and without this cytokine, 
effective granuloma formation is diminished and bacterial numbers rapidly increase 
resulting in the death of the mice (Engele et al., 2002). 
 
The importance of IFN-γ in protective immunity against TB derives from two separate 
lines of evidence. Studies using IFN-γ knockout mice have shown definitively that  
IFN-γ, a cytokine that activates infected macrophages to kill intracellular bacteria, is 
vitally important for protection against M. tuberculosis (Cooper et al., 1993). Studies of  
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Table1. 2. Important cytokines during M. tuberculosis infection 
Cytokine Function Source 
TNF-α Granuloma formation. Regulate 
MФ function 
DC, MФ, neutrophils, T-cells 
IFN-γ ↑ MФ bactericidal activity MФ, neutrophils, T & B cells 
IL-12 ↑ IFN-γ production by T-cells 
granuloma formation inducing 
TH1 response  
MФ 
IL-18 Act together with IL-12 to induce 
IFN-γ  
MФ 
IL-1α MФ activation 
T-cell activation 
MФ 
IL-4 Th2 response  
B cell activation 
T-cells 
IL-10 Suppressive effect on MФ 
Inhibits production of TNF-α 
T-cells 
TGF-β Suppression of lymphocytes  
Modulation of proinflammatory 
cytokine 
MФ, T & B cells 
MФ- macrophages,   DC- dendritic cell. 
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humans who are homozygous for a mutation in IFN-γ receptors show that they are 
extremely sensitive to fatal mycobacterial infection (Jouanguy et al., 1996, Newport     
et al., 1996). Individuals who lack the ability to produce IFN-γ, or who cannot respond 
to it or lack the receptor for it, are susceptible to severe systemic infection with 
mycobacterial species that do not usually cause significant disease in immunocompetent 
individuals (Jouanguy et al., 1996, Newport et al., 1996). 
 
Early studies indicated that the purified protein derivative (PPD) of  M. tuberculosis 
induces the proinflammatory cytokine IL-1 (Wallis et al., 1996) and TNF-α  (Valone et 
al., 1988). On the other hand the intact M. tuberculosis, but not its PPD, was strong in 
the induction of IL-12 (which stimulates IFN-γ production) in monocytes (Fulton et al., 
1998). Both TNF-α and IFN-γ induce microbicidal pathways by producing reactive 
oxygen and nitrogen intermediaries in phagocytes (Flesch and Kaufmann, 1990). 
 
1.9. Mycobacterial antigens  
As previously described, protection against TB is provided through cell mediated 
immune responses, and the production of IFN-γ by both CD4+ and CD8+ T-cells appears 
to be essential components of resistance to M. tuberculosis. A primary criterion for 
selecting candidate antigens for vaccine design is their ability to induce protective T-cell 
responses. Thus, it is required that the major antigens and epitopes of M. tuberculosis be 
identified (see Section 1.11.2). A variety of M. tuberculosis antigen preparations 
obtained from the cell wall, cytosolic fractions and culture filtrates have been reported 
(Young et al., 1992, Mustafa, 1996, 2002). These antigens have several hundred amino 
acids, whereas T-cells usually recognize epitopes ranging between 8 and 20 amino acids 
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presented in the context of MHC molecules. Thus a complete protein antigen may have 
several T-cell epitopes. To identify the T-cell epitopes mediating protective immunity, 
several studies have been conducted to identify and characterize the epitopes of M. 
tuberculosis antigens recognized by human T-cells of the Th1 type (Mustafa, 2002).  
 
Although bacteria consist of several thousands of proteins, the range of proteins 
recognized by antibodies produced in different laboratories was restricted leading to the 
concept of immunodominance, i.e. that there were certain proteins which were 
selectively recognized by the immune system. When these antigenic proteins were 
identified by screening mycobacterial recombinant DNA expression libraries with 
antibody probes (Young et al., 1985), most of these antigens were found to belong to a 
group of molecules whose function is to protect the organism from environmental 
damage (Young et al., 1988). Testing of these antigens with T-cell lines and clones 
showed that human T-cells recognized most of them (Mustafa, 1988, Oftung et al., 
1998, Mustafa et al., 1999). Among these recombinant antigens is the antigen 18-kDa 
that belongs to the heat shock protein (hsp)18 family (Booth et al., 1988), the 65-kDa 
which belongs to hsp65 family (Shinnick, 1987) and the 70-kDa which belongs to hsp70 
family (Garsia et al., 1989). These antigens were also recognized by human T-cells as 
natural mycobacterial antigens (Mustafa, 2002). A novel 24 kDa secreted lipoprotein 
was also identified by direct screening of recombinant DNA libraries with human T-cell 
clones. Interestingly the T-cell epitopes of this antigen were found to be common to the 
two most important pathogenic mycobacterial species M. tuberculosis and M. leprae 
and was lacking in the vaccine strains of BCG and most environmental mycobacteria 
(Oftung et al., 1997, Mustafa et al., 1998). 
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Secreted protein antigens present in culture filtrate preparations have also been studied 
extensively. These studies showed that these antigens induce CMI responses and are 
protective against TB in mice and guinea pigs (Andersen, 1994, Horwitz et al., 1995, 
Roberts et al., 1995). These proteins were separated into discrete fractions according to 
size by polyacrylamide gel electrophoresis and then tested for T-cell reactivity and 
proliferation (Abou-zeid et al., 1987). Mouse models of TB infection have shown that 
T-cells from the memory immune mice secreted large quantities of IFN-γ in response to 
two fractions of the culture filtrate protein known as the 6-10 kDa proteins and antigen 
85 (Ag85) complex (Andersen et al., 1995). Testing of human T-cells with purified 
antigens of M. tuberculosis in proliferation assays and for IFN-γ production showed that 
the secreted antigens, which  include Ag85B, ESAT6, MPT64 and MPB70, were better 
stimulators of human T-cells compared the antigens of cytosolic origin (Mustafa et al., 
1998, Ravn et al., 1999).  
 
Mice immunized with plasmid DNA encoding the Ag85A (DNA-Ag85A) showed a 
strong T-cell response when restimulated in vitro with synthetic 20-mer peptides of the 
native Ag85. This response was characterized by elevated levels of Th1-type cytokines, 
IL-2 and IFN-γ. In addition, DNA-Ag85A vaccines conferred protection upon 
subsequent infection with live mycobacteria (Denis et al., 1998).  
 
1.10. Diagnosis of TB.  
The diagnosis of TB is established when tubercle bacilli are identified in specimens 
such as sputum, urine, and body fluids. The most common specimen received for 
tubercle examination is sputum (Kalafer, 1991). Acid fast staining of smears to identify 
the bacillus is a rapid technique, but it has low sensitivity and cannot differentiate 
